Thus, efficient inhibitors of B0AT1 could be used to treat metabolic diseases such as NASH, NAFLD, phenylketonuria, urea cycle deficiency, and related disorders. This evidence concerns the gene SLC6A19 and metabolic dysfunction-associated steatohepatitis.